318 related articles for article (PubMed ID: 9920256)
1. Billion-dollar market blossoms as botanicals take root.
Glaser V
Nat Biotechnol; 1999 Jan; 17(1):17-8. PubMed ID: 9920256
[No Abstract] [Full Text] [Related]
2. Balancing US patent and FDA approval processes: strategically optimizing market exclusivity.
Fernandez DS; Huie JT
Drug Discov Today; 2004 Jun; 9(12):509-12. PubMed ID: 15183155
[No Abstract] [Full Text] [Related]
3. The decreased number of new drug approvals (NDAs) has been a topic of considerable debate over the past decade. Preface.
Enna SJ; Williams M
Adv Pharmacol; 2009; 57():xi-ii. PubMed ID: 19945649
[No Abstract] [Full Text] [Related]
4. SuperGenerics: a better alternative for biogenerics.
Charles SA
Drug Discov Today; 2005 Apr; 10(8):533-5. PubMed ID: 15837591
[No Abstract] [Full Text] [Related]
5. Market watch: upcoming market catalysts in Q2 2011.
Jeng R
Nat Rev Drug Discov; 2011 Apr; 10(4):248. PubMed ID: 21455226
[No Abstract] [Full Text] [Related]
6. A precarious balancing act--the role of the FDA as protector of public health and industry wealth.
McCabe AR
Suffolk Univ Law Rev; 2003; 36(3):787-819. PubMed ID: 16493844
[No Abstract] [Full Text] [Related]
7. New clinical trials policy at FDA.
Vastag B
Nat Biotechnol; 2006 Sep; 24(9):1043. PubMed ID: 16964196
[No Abstract] [Full Text] [Related]
8. Market watch: upcoming market catalysts in Q1 of 2010.
Rosenthal J
Nat Rev Drug Discov; 2010 Jan; 9(1):11. PubMed ID: 20043022
[No Abstract] [Full Text] [Related]
9. How pharmacogenomics will impact the federal regulation of clinical trials and the new drug approval process.
Binzak BA
Food Drug Law J; 2003; 58(1):103-27. PubMed ID: 12739592
[No Abstract] [Full Text] [Related]
10. The problem of new uses.
Eisenberg RS
Yale J Health Policy Law Ethics; 2005; 5(2):717-39. PubMed ID: 16052897
[No Abstract] [Full Text] [Related]
11. Cautious welcome for FDA pharmacogenomics guidance.
Katsnelson A;
Nat Biotechnol; 2005 May; 23(5):510. PubMed ID: 15877053
[No Abstract] [Full Text] [Related]
12. Market exclusivity for biologics.
Wheadon DE
N Engl J Med; 2010 Feb; 362(7):661; author reply 661-2. PubMed ID: 20164494
[No Abstract] [Full Text] [Related]
13. Experimental use and the Orphan Drug Act: a biotechnology conundrum.
Koivuniemi PJ
Nat Biotechnol; 1996 Apr; 14(4):511-2. PubMed ID: 9630930
[No Abstract] [Full Text] [Related]
14. Clinical research: outlook from industry.
Echols R
Clin Perform Qual Health Care; 1996; 4(2):113-4. PubMed ID: 10156942
[No Abstract] [Full Text] [Related]
15. New guides to herbal remedies.
Harv Womens Health Watch; 1999 Feb; 6(6):2-3. PubMed ID: 9973889
[No Abstract] [Full Text] [Related]
16. Market watch: upcoming market catalysts in Q1 2013.
Inui E
Nat Rev Drug Discov; 2013 Jan; 12(1):12. PubMed ID: 23274459
[No Abstract] [Full Text] [Related]
17. Market watch: Upcoming market catalysts in Q3 2013.
Roybal D
Nat Rev Drug Discov; 2013 Jul; 12(7):496. PubMed ID: 23812261
[No Abstract] [Full Text] [Related]
18. Market watch: Upcoming market catalysts in Q4 2013.
Fong S
Nat Rev Drug Discov; 2013 Oct; 12(10):731. PubMed ID: 24080689
[No Abstract] [Full Text] [Related]
19. A critical tipping point.
Zuckerman MB
US News World Rep; 2002 Apr; 132(13):72. PubMed ID: 11993366
[No Abstract] [Full Text] [Related]
20. Alternative medicine--the risks of untested and unregulated remedies.
Angell M; Kassirer JP
N Engl J Med; 1998 Sep; 339(12):839-41. PubMed ID: 9738094
[No Abstract] [Full Text] [Related]
[Next] [New Search]